ID: ALA571852

Max Phase: Preclinical

Molecular Formula: C15H12F2N2O6S

Molecular Weight: 386.33

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(=O)NS(=O)(=O)c1ccc(-c2ccn(C(F)F)c(=O)c2)cc1C(=O)O

Standard InChI:  InChI=1S/C15H12F2N2O6S/c1-8(20)18-26(24,25)12-3-2-9(6-11(12)14(22)23)10-4-5-19(15(16)17)13(21)7-10/h2-7,15H,1H3,(H,18,20)(H,22,23)

Standard InChI Key:  QWGFBJWNBZWBPO-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 386.33

Molecular Weight (Monoisotopic): 386.0384

AlogP: 1.43

#Rotatable Bonds: 5

Polar Surface Area: 122.54

Molecular Species: ACID

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 2.05

CX Basic pKa:

CX LogP: 0.94

CX LogD: -3.53

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.80

Np Likeness Score: -0.97

References

1. Chowdhury MA, Abdellatif KR, Dong Y, Das D, Yu G, Velázquez CA, Suresh MR, Knaus EE..  (2009)  Synthesis and biological evaluation of salicylic acid and N-acetyl-2-carboxybenzenesulfonamide regioisomers possessing a N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore: dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.,  19  (24): [PMID:19884005] [10.1016/j.bmcl.2009.10.083]

Source

Source(1):

• Scientific Literature